- « Previous Releases | Next Releases »
DUBLIN, Ireland, May 1, 2012 (GLOBE NEWSWIRE) -- In accordance with Rule 2.10 of the Irish Takeover Rules, Warner Chilcott plc (Nasdaq:WCRX) (the "Company") confirms that, as of the close of business on April 30, 2012, the Company's issued share capital consisted of 250,421,544 ordinary shares, par value US$0.01 per share (the "Ordinary Shares"). The CUSIP number for the Ordinary Shares is G94368100.
The Company also confirms that, as of the close of business on April 30, 2012, there were outstanding 505,729 restricted share units (the "Restricted Share Units") and 6,041,708 options to purchase Ordinary Shares (the "Share Options") granted by the Company. Upon vesting, each Restricted Share Unit entitles the holder to receive one Ordinary Share, and each Share Option entitles the holder to purchase one Ordinary Share at the applicable exercise price.
Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare, gastroenterology, dermatology and urology segments of the branded pharmaceuticals market, primarily in North America. We are a fully integrated Company with internal resources dedicated to the development, manufacturing and promotion of our products. WCRX-G
A person interested in 1% or more of any relevant securities in the Company may have disclosure obligations under Rule 8.3 of the Irish Takeover Rules. This requirement will continue until the offer period ends.
The directors of the Company accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case) the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.
Goldman Sachs International, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for the Company and for no-one else in connection with the matters set out in this announcement and will not be responsible to any person other than the Company for providing the protections afforded to clients of Goldman Sachs International, nor for providing advice in relation to the matters set out in this announcement.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (DIRECTLY OR INDIRECTLY) IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THIS WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.